The Tissue Bank (Core C) provides the infrastructure to provide specimens from patients with myeloproliferative neoplasms (MPN) to investigators performing translational research for the purpose of developing innovative therapies for MPN pafients. The functions of the tissue bank are to: 1) acquire MPN tissues, 2) act as a repository for MPN tissues, 3) distribute MPN fissues for research, and 4) facilitate the performance of biomarker assays by distributing tissues to core laboratories. Tissues are available to members of the MPD Research Consortium (MPD-RC) and to the scientific community at large for the performance of translational research. Core C is an essential shared resource that enables translational research that will result in improved diagnosis and staging of MPN and ultimately lead to the development of molecularly targeted therapies.
The specific aims of Tissue Bank Core C are to: 1) Receive, process, cryopreserve, and store tissues from MPN patients diagnosed at MPD-RC clinical sites in an efficient, organized manner according to standard operafing procedures (SOPs). 2) Provide a central repository for MPN tissues that are associated with basic data stored in the web-based data bank maintained by Biostatistics and Data Management Core B. These basic data include clinical, laboratory and familial demographic data that enable selection and distribution of tissues best suited for each translational research project. 3) Make the cryopreseved tissues readily available to the MPD Consortium investigators and scientific community at large for research studies. 4) Facilitate the performance of biomarker assays designed to predict disease progression, thrombofic complications, and therapeutic response, by receiving, processing, cryopreserving, and storing tissues from MPN patients, and distributing these tissues to consortium biomarker assay labs. These tissues are collected from patients at diagnosis and at intervals designated in individual protocols described in Project 6. Biomarker assays provide data that are anticipated to correlate with clinical trial endpoints. Specimens from more than 600 patients are cun-ently banked in Core C. Tissues from more than 275 patients have been distributed for research to members of the MPD-RC and the scientific community at large.
Translational research depends on the availability of specimens from pafients. MPNs are relatively uncommon resulting in a paucity of specimens available. Core C currently maintains one of the world's largest inventories of MPN specimens (from 600 patients) available for research by Consortium members and the scientific community at large. All patient samples are de-identified and electronically linked to clinical and demographic data to ensure accurate diagnosis and interpretation of data.
|Wang, Xiaoli; Haylock, David; Hu, Cing Siang et al. (2016) A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells. Blood 127:3398-409|
|Divoky, Vladimir; Song, Jihyun; Horvathova, Monika et al. (2016) Delayed hemoglobin switching and perinatal neocytolysis in mice with gain-of-function erythropoietin receptor. J Mol Med (Berl) 94:597-608|
|Spangrude, Gerald J; Lewandowski, Daniel; Martelli, Fabrizio et al. (2016) P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1 low Model of Myelofibrosis. Stem Cells 34:67-82|
|Migliaccio, Anna Rita (2016) To condition or not to condition-That is the question: The evolution ofÂ nonmyeloablative conditions for transplantation. Exp Hematol 44:706-12|
|Lu, Min; Xia, Lijuan; Liu, Yen-Chun et al. (2015) Lipocalin produced by myelofibrosis cells affects the fate of both hematopoietic and marrow microenvironmental cells. Blood 126:972-82|
|Wang, Xiaoli; Cho, Sool Yeon; Hu, Cing Siang et al. (2015) C-X-C motif chemokine 12 influences the development of extramedullary hematopoiesis in the spleens of myelofibrosis patients. Exp Hematol 43:100-9.e1|
|Kovacsovics-Bankowski, Magdalena; Kelley, Todd W; Efimova, Olga et al. (2015) Changes in peripheral blood lymphocytes in polycythemia vera and essential thrombocythemia patients treated with pegylated-interferon alpha and correlation with JAK2(V617F) allelic burden. Exp Hematol Oncol 5:28|
|Swierczek, S; Lima, L T; Tashi, T et al. (2015) Presence of polyclonal hematopoiesis in females with Ph-negative myeloproliferative neoplasms. Leukemia 29:2432-4|
|Funnell, Alister P W; Prontera, Paolo; Ottaviani, Valentina et al. (2015) 2p15-p16.1 microdeletions encompassing and proximal to BCL11A are associated with elevated HbF in addition to neurologic impairment. Blood 126:89-93|
|Falchi, Mario; Varricchio, Lilian; Martelli, Fabrizio et al. (2015) Dexamethasone targeted directly to macrophages induces macrophage niches that promote erythroid expansion. Haematologica 100:178-87|
Showing the most recent 10 out of 164 publications